Amylyx Pharmaceuticals (AMLX) Other Working Capital Changes (2022 - 2026)

Amylyx Pharmaceuticals' Other Working Capital Changes history runs 5 years deep, the most recent figure standing at -$327000.0 for Q1 2026.

• On a quarterly basis, Other Working Capital Changes rose 45.41% year-over-year to -$327000.0 in Q1 2026; TTM through Mar 2026 was -$890000.0, a 61.51% increase from a year earlier, with the FY2025 full-year figure at -$1.2 million, up 48.49% from the prior year.
• Other Working Capital Changes retreated to -$327000.0 in Q1 2026 per AMLX's latest filing, from $23000.0 in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $6.3 million in Q3 2023 and bottomed at -$4.4 million in Q2 2022.
• The 5-year median for Other Working Capital Changes is -$1.4 million (2026), against an average of -$335823.5.
• Across the five-year window, Other Working Capital Changes slumped 16266.67% in 2023 and soared 103.92% in 2025, its largest moves.
• Year by year, Other Working Capital Changes stood at -$481000.0 in 2022, then retreated by 10.6% to -$532000.0 in 2023, then dropped by 10.15% to -$586000.0 in 2024, then surged by 103.92% to $23000.0 in 2025, then slumped by 1521.74% to -$327000.0 in 2026.
• Per Business Quant, the three latest AMLX Other Working Capital Changes figures stand at -$327000.0 (Q1 2026), $23000.0 (Q4 2025), and -$27000.0 (Q3 2025).